45. David Farber Discusses the Implications of CMS' Recent National Coverage Decision Proposal For FDA Approved Alzheimer's Treatments

On January 11th, the Centers for Medicare & Medicaid Services released an NCD proposal that would require “coverage with evidence development” for monoclonal antibody therapies aimed at amyloid for the treatment of Alzheimer’s disease. CMS’ coverage determination is deeply troubling, as it restricts Medicare recipient access to critical treatment.Here today to discuss CMS’ national coverage determination and its implications on patients who suffer from Alzheimer’s Disease and other dementias is David Farber, an expert on international reference pricing, healthcare reimbursement, and the regulatory approval process for drugs and medical devices.